Zenas BioPharma (ZBIO) Enterprise Value (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Enterprise Value of -$717.2 million for Q1 2026, down 66.78% year-over-year from -$2.2 billion in Q1 2025, and down 108.98% quarter-over-quarter from -$343.2 million in Q4 2025.
Zenas BioPharma (ZBIO) Enterprise Value (2023 - 2026) Analysis & Trends
Zenas BioPharma's Enterprise Value history runs 4 years deep, the most recent figure standing at -$717.2 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 66.78% year-over-year to -$717.2 million; the TTM figure through Mar 2026 stood at -$717.2 million (down 66.78% YoY), while the FY2025 annual figure was -$343.2 million, up 2.16% from the prior year.
- Enterprise Value for Q1 2026 stood at -$717.2 million, down from -$343.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$37.2 million in Q1 2024, with the low at -$717.2 million in Q1 2026.
- The 4-year median for Enterprise Value is -$343.2 million (2025), against an average of -$300.2 million.
- Peak annual rise in Enterprise Value reached 2.16% in 2025, while the deepest fall reached 1054.74% in 2025.
- Zenas BioPharma's Enterprise Value stood at -$56.9 million in 2023, then slumped by 516.93% to -$350.8 million in 2024, then gained by 2.16% to -$343.2 million in 2025, then plunged by 108.98% to -$717.2 million in 2026.
- Business Quant data shows ZBIO's Enterprise Value at -$717.2 million in Q1 2026, -$343.2 million in Q4 2025, and -$476.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | -1.12 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.12 Bn |
| Mar 31, 2026 | -717.21 Mn |
| Dec 31, 2025 | -343.19 Mn |
| Sep 30, 2025 | -476.92 Mn |
| Jun 30, 2025 | -273.28 Mn |
| Mar 31, 2025 | -430.03 Mn |
| Dec 31, 2024 | -350.77 Mn |
| Sep 30, 2024 | -360.13 Mn |
| Jun 30, 2024 | -184.02 Mn |
| Mar 31, 2024 | -37.24 Mn |
| Dec 31, 2023 | -56.86 Mn |
| Sep 30, 2023 | -72.31 Mn |